APA

Naegelin Y., Rasenack M., Andelova M., Von Felten S., Fischer-Barnicol B., Amann M., Mehling M., Kappos L., Sprenger T. & Derfuss T. (20181213). Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. : Multiple sclerosis and related disorders.

Chicago

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T and Derfuss T. 20181213. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. : Multiple sclerosis and related disorders.

Harvard

Naegelin Y., Rasenack M., Andelova M., Von Felten S., Fischer-Barnicol B., Amann M., Mehling M., Kappos L., Sprenger T. and Derfuss T. (20181213). Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. : Multiple sclerosis and related disorders.

MLA

Naegelin Y, Rasenack M, Andelova M, Von Felten S, Fischer-Barnicol B, Amann M, Mehling M, Kappos L, Sprenger T and Derfuss T. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis. : Multiple sclerosis and related disorders. 20181213.